Nivolumab plus Cabozantinib Versus Sunitinib for First-line Treatment of Advanced Renal Cell Carcinoma: 3-year Follow-up from the Phase 3 CheckMate 9ER Trial : Episode 4

Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC

May 8, 2023

By Toni K. Choueiri, MD
Rohit Gosain, MD

News

Video

Panelists continue to discuss long-term follow-up data from the CheckMate 9ER trial, focusing on treatment-related adverse events seen in patients with ccRCC treated with nivolumab plus cabozantinib.

EP: 1.Overview of ccRCC and Introduction to the CheckMate 9ER Trial

EP: 2.A Closer Look at Study Design and Patient Demographics from the CheckMate 9ER Trial

EP: 3.CheckMate 9ER: Progression-free Survival, Overall Survival, and Objective

Now Viewing

EP: 4.Adverse Events Following Use of Nivolumab Plus Cabozantinib in Patients With Advanced ccRCC

EP: 5.A Post-hoc Analysis of CheckMate 9ER Data and Study Conclusions

EP: 6.Clinical Insights Surrounding CheckMate 9ER Updates and Use of Nivolumab Plus Cabozantinib in ccRCC

EP: 7.Recap: Combination Therapy Shows Promise in Renal Cell Carcinoma

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!